Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen.
about
HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsHLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.Copy number variation in Thai population.Genetic screening for metabolic and age-related complications in HIV-infected persons.Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort studyPolymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients.HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivityThe use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in ThailandIndividualization of antiretroviral therapy.Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260sDyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children.Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Mitochondrial subhaplogroups and differential risk of stavudine-induced lipodystrophy in Malawian HIV/AIDS patients.A success story in pharmacogenomics: genetic ID card for SJS/TEN.
P2860
Q28088839-E2E05A6A-51DD-4769-B477-A5BEC7FEF72AQ31154955-36A0CFBD-F18F-475E-A523-93C681F1B925Q34041126-4FA254AA-B220-48E4-8DBF-0440A857BBA4Q34389768-B8DDCC2D-EA04-436D-8354-E0C87E2B19B9Q34484483-0B0F0CB5-4A8E-402F-B440-B2F0E6031A95Q34806335-B9B05DAF-CC6C-4AE0-88E2-BE020F2F0A0DQ34999573-63427801-F990-4D4C-B0A5-A952A9DE6636Q36267146-364C011E-4332-44F7-A6F4-56AFB7B29032Q36441423-69785689-640E-4CFE-A120-D42E8901FFE6Q36676379-2E9DC8FE-0486-4EBF-97FE-9B4F57C12A7CQ37720716-5E85B9E9-62EF-441D-9D83-F383D204F311Q37724319-5636BED8-3E1E-4EF6-AC3C-CBB8C1119F06Q37945715-1D3E9EE0-8A45-4A49-A6AE-4E20DB6B6B2DQ38051400-AFB6FBFF-8532-4CCE-8518-76978D1A8F31Q42252873-10C46438-96C7-4018-9788-6A1577F4C253Q50877130-9BA976CE-C18A-41B2-B2DC-6885D182710F
P2860
Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@ast
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@en
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@nl
type
label
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@ast
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@en
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@nl
prefLabel
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@ast
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@en
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@nl
P2093
P50
P356
P1476
Association between HLA-B*4001 ...... aining antiretroviral regimen.
@en
P2093
Angkana Charoenyingwattana
Chupong Thongnak
Soranun Chantarangsu
Surakameth Mahasirimongkol
Surat Komindr
Taisei Mushiroda
Wasun Chantratita
Wittaya Wangsomboonsiri
Yusuke Nakamura
P304
P356
10.1086/650003
P407
P50
P577
2010-02-01T00:00:00Z